Analysis Arbutus Biopharma Corporation (0SGC)
5/29/2024
Analysis of Arbutus Biopharma Corporation (0SGC)
Arbutus Biopharma Corporation (0SGC) has shown a recent uptrend in its stock price, with the price closing at 3.30200 on May 28th, 2024. The Relative Strength Index (RSI) indicator is at 68.91445, indicating that the stock may be approaching overbought levels.The Moving Average Convergence Divergence (MACD) indicator is positive at 0.12862, with the MACD line above the signal line, suggesting bullish momentum. The Moving Average (MA) indicator is also positive at 2.92138.
Overall, based on the technical indicators, Arbutus Biopharma Corporation seems to be in a bullish phase, but investors should be cautious of a potential pullback due to the high RSI level.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided at this time. The previous results were reported on February 27, 2025, through the Transfer Agent. Before that, on January 31, 2025, the results were released after hours. The results for October 31, 2024, were not provided at the time. On August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.1. Financials:
- Cash Flow: Operating cash flow TTM is $110,563,000,320 and levered free cash flow TTM is $84,726,874,112.
- Balance Sheet: Total cash MRQ is $67,150,000,128, total debt MRQ is $104,590,000,128, current ratio MRQ is 1.037, book value per share MRQ is $4.837, total cash per share MRQ is $4.379, total debt to equity MRQ is 140.968.
- Profit Margin: 26.306%.
- Income Statement: EBITDA is $131,393,000,000, revenue TTM is $381,623,009,280, diluted EPS TTM is $6.44, gross profit TTM is $169,148,000,000, revenue per share TTM is $24.537, net income to common TTM is $100,389,003,264, quarterly revenue growth is -4.3%, quarterly earnings growth YoY is -2.2%.
- Operating Margin: 30.743%.
- Return on Assets TTM: 22.073999%.
- Return on Equity TTM: 147.25%.
2. Stock Statistics:
- Short Ratio: 1.66.
- Float Shares: 15,308,320,742.
- Shares Short: 94,308,265.
- Average 10-Day Volume: 52,903,608.
- Average 90-Day Volume: 62,823,269.
- Shares Outstanding: 15,334,099,968.
- Percent Held by Insiders: 5.22%.
- Percent Held by Institutions: 57.555%.
- Short Percent of Shares Outstanding: 0.62%.
3. Valuation Metrics:
- PEG Ratio: 26.213001.
- Forward PE: 26.213001.
- Trailing PE: 29.428572.
- Enterprise Value: $2,948,462,018,560.
- Price to Book MRQ: 39.181313.
- Price to Sales TTM: 7.6151557.
- Enterprise to EBITDA: 22.745.
- Enterprise to Revenue: 7.726.
- Market Capitalization: $2,906,118,684,672.
4. Stock Price Summary:
- Beta: 1.264.
- 50-Day Moving Average: $173.6936.
- 200-Day Moving Average: $180.7906.
- 52-Week Low: $164.08.
- 52-Week High: $199.62.
- 52-Week Change: 8.253%.
5. Dividends and Splits:
- Payout Ratio: 14.93%.
- Dividend Date: May 16, 2024.
- Last Split Date: August 31, 2020.
- Ex-Dividend Date: May 10, 2024.
- Last Split Factor: 4-for-1 split.
- Forward Annual Dividend Rate: $1.
- 5-Year Average Dividend Yield: 0.73%.
- Forward Annual Dividend Yield: 0.5266761603816345%.
- Trailing Annual Dividend Rate: $0.97.
- Trailing Annual Dividend Yield: 0.5108758755701854%.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales have been increasing steadily over the past four years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. The gross profit margin has been relatively stable, ranging from 38% to 44% over the same period.
3. Operating income has also shown a consistent growth trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
4. Net income has been increasing year over year, from $57.4 billion in 2020 to $97 billion in 2023.
5. Earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trajectory.
6. The company has been able to maintain a healthy EBITDA margin, hovering around 33% to 35%.
7. Despite an increase in income tax expenses, the company has managed to grow its net income continuously.
8. The company has been able to effectively manage its operating expenses, keeping them in check relative to its growing revenues.
9. Non-operating interest expenses have been relatively stable, indicating a consistent financial management approach.
10. The number of basic and diluted shares outstanding has remained constant over the years, indicating no significant dilution of shares.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been increasing over the years, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with some fluctuations in different areas that may require further analysis.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39
Based on these estimates, we can see a generally positive trend in the expected earnings per share for both the upcoming quarters and years, with an increase compared to the previous year's EPS in most cases. This indicates potential growth and improvement in the company's financial performance according to analysts' projections.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company over the specified periods, as indicated by the positive sales growth rates projected by the analysts.
Growth estimates
Based on the consensus estimates provided:- The current year growth rate is 7.5%
- The next quarter growth rate is 4.8%
- The current quarter growth rate is 5.6%
- The next year growth rate is 9.7%
- The next 5 years compound annual growth rate (CAGR) is 11%
- The past 5 years compound annual growth rate (CAGR) is 20.15%
It can be observed that the growth rates are expected to vary across different time periods, with a higher growth rate projected for the next 5 years compared to the current and past periods. This indicates a positive outlook for the company's growth trajectory, especially in the long term.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median and average price above the current price. However, there is a wide range between the low and high forecasts, indicating some uncertainty or differing opinions among analysts.
MACD of 0SGC
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
